Jose Ignacio M. V.
- Country
- Spain
- Department
- Medical Oncology
Research Overview
- Comparative Study of Onivyde from Two Production Sites in Adults with Metastatic Pancreatic Adenocarcinoma
- Evaluation of Overall Survival in Metastatic Pancreatic Ductal Adenocarcinoma with SBP-101, Nab-Paclitaxel, and Gemcitabine Therapy
- Phase 3 Study of Trastuzumab Deruxtecan with Chemotherapy ± Pembrolizumab vs. Chemotherapy with Trastuzumab ± Pembrolizumab in HER2-Positive Gastric/GEJ Cancer
Data & Insights
Has run more than one trial at 55 of 203 partner sites.
Specializations
Pancreatic Cancer Research
The investigator specializes in the treatment of advanced pancreatic cancer, with particular emphasis on metastatic pancreatic adenocarcinoma and pancreatic ductal adenocarcinoma.
- Advanced Pancreatic Cancer Management
- Metastatic Disease Treatment
- Novel Therapeutic Combinations
Their research encompasses innovative treatment approaches for patients with advanced stages of pancreatic malignancies.
Therapeutic Innovation
The investigator focuses on evaluating combination therapy approaches in pancreatic cancer treatment, including the assessment of novel therapeutic agents alongside established treatments.
- Combination Treatment Strategies
- Treatment Optimization
- Clinical Outcomes Assessment
Their work involves investigating therapeutic efficacy through comparative studies of different treatment modalities.
Clinical Development
The investigator's expertise extends to survival outcome research and the evaluation of treatment manufacturing processes in advanced pancreatic cancer therapy.
- Overall Survival Assessment
- Manufacturing Site Comparisons
- Treatment Standards Development
Their research contributes to establishing treatment standards for advanced pancreatic cancer patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.